Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Eager for Its Active Involvement in Drug Pricing Debates: Chief
January 18, 2017
- JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs
January 18, 2017
- JGA Corrects Generic Share Data for Past 3 Years; July-Sept. Share at 65.1%
January 16, 2017
- With Annual Revisions, Drug Wholesalers Will Be Negotiating Delivery Prices All Year: JPWA Chief
January 12, 2017
- Tokyo Pharma Chief Naito Prods Govt to Secure Predictability of Pricing System
January 10, 2017
- Building Personal Relationships Will Be Crucial: FPMAJ Director General
January 6, 2017
- Annual Price Revisions Must Not Adversely Affect Distribution Environment: JPWA
December 26, 2016
- Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January
December 26, 2016
- FPMAJ Accepts PMDA’s Fee Raise Plan, but Wants Tradeoff
December 16, 2016
- JMA Wants Adjustment Rate as High as 5%: Yokokura
December 15, 2016
- Daratumumab Affects Transfusion Tests, Scientific Societies Warn
December 13, 2016
- Ongoing Discussions without Chuikyo Deplorable: JPWA Head
December 12, 2016
- Annual Price Revisions Will Demotivate Pharmas, Foreign HQs Harboring Serious Concerns: PhRMA Japan Chief
December 9, 2016
- Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
December 6, 2016
- JPWA Shows Firm Opposition to Annual Revisions
December 5, 2016
- Annual Price Revisions of All Drugs Unacceptable: JMA Chief
December 1, 2016
- Japan, US, Europe Trade Groups Vehemently Oppose Annual Price Revisions
December 1, 2016
- JGA Rebuts Govt Panel Members’ Pricing Reform Proposals in Emergency Statement
November 30, 2016
- Drug Pricing Rules Should Be Fundamentally Reviewed: JMA Chief
November 28, 2016
- EFPIA, PhRMA “Regret” Out-of-Cycle Price Slash for Opdivo
November 22, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…